Enveric Biosciences Inc. - news published 259 - readings 4.281

BACK
Enveric Biosciences Inc.

Enveric Biosciences Inc.

Enveric Biosciences Reports Second Quarter 2025 Financial and Corporate Results (Form 8-K)

Enveric Biosciences Reports Second Quarter 2025 Financial and Corporate Results Q2 marked a critical inflection point in EB-003 development with mechanism confirmation, therapeutic opportunity expansion, IND-enabling progress, and continued strengthening of Enveric's differentiated neuroplastogen pipeline and IP platform. Q2 financial results were consistent with overall perfo ...

Continue reading
14.08.2025
Enveric Biosciences Inc.

Enveric Biosciences Inc.

Quarterly Report for Quarter Ending March 31, 2025 (Form 10-Q)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended: March 31, 2025 OR ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from ___ to ___ Commission File Numb ...

Continue reading
14.05.2025
Enveric Biosciences Inc.

Enveric Biosciences Inc.

Enveric Biosciences Reports First Quarter 2025 Financial and Corporate Results (Form 8-K)

Enveric Biosciences Reports First Quarter 2025 Financial and Corporate Results Corporate, Business and Product Development Highlights: ● Unveiled EVM401 Series with new U.S. Patent for mescaline derivative compounds ● Added to suite of intellectual property for EB-003, a neuroplastogen targeting undertreated mental health indications ● Signed two licensing agreements for ...

Continue reading
14.05.2025
Enveric Biosciences Inc.

Enveric Biosciences Inc.

Amendment to Registration Statement - Specified Transactions (Form S-3/A)

As filed with the U.S. Securities and Exchange Commission on April 9, 2025 Registration No. 333-280721 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 AMENDMENT NO. 1 TO FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ENVERIC BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 95-4484725 (State or other jur ...

Continue reading
10.04.2025
Enveric Biosciences Inc.

Enveric Biosciences Inc.

Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2024 (Form 8-K)

Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2024 Product Development Highlights: ● Advanced pre-IND and research activities including confirmation of oral bioavailability and significant brain exposure for EB-003, a novel potential first-in-class neuroplastogenic molecule designed to treat severe mental ...

Continue reading
31.03.2025
Enveric Biosciences Inc.

Enveric Biosciences Inc.

Annual Report for Fiscal Year Ending December 31, 2024 (Form 10-K)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the annual period ended: December 31 , 2024 OR ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from ___ to ___ Commission File Number ...

Continue reading
28.03.2025
Enveric Biosciences Inc.

Enveric Biosciences Inc.

Initial Registration Statement for Employee Benefit Plan (Form S-8)

As filed with the Securities and Exchange Commission on March 24, 2025 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Enveric Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 95-4484725 (State or other jurisdiction of incorporation or ...

Continue reading
24.03.2025
Enveric Biosciences Inc.

Enveric Biosciences Inc.

Enveric Biosciences Launches Request For Proposals Solicitation Process for PsyAI Trademark

Press Releases Enveric Biosciences Launches Request-For-Proposals Solicitation Process for PsyAI Trademark By wpengine March 6, 2025 No Comments CAMBRIDGE, Mass. - Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of de ...

Continue reading
06.03.2025